文献速递系统性红斑狼疮

SLE-DAS与SLEDAI-2K预测SLE器官损伤累积的能力:瑞典7年真实世界队列研究

Ability of SLE-DAS and SLEDAI-2K to predict damage accrual in SLE: a real-world 7-year cohort study from Sweden.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该研究纳入瑞典林雪平大学医院335例SLE患者、3582次门诊访视,比较SLE-DAS与SLEDAI-2K等活动度指标预测器官损伤累积的能力。结果显示平均SLE-DAS在3年、5年和7年随访中均为SDI增加的独立预测因子,且预测能力优于SLEDAI-2K。

要点

  • 平均SLE-DAS可独立预测3年、5年和7年SDI增加。
  • 平均SLEDAI-2K仅在5年随访中预测SDI增加。
  • SLE-DAS预测损伤累积的能力优于SLEDAI-2K(AIC/BIC更低)。

核心结论

  • 在瑞典真实世界环境中,SLE-DAS在预测SLE器官损伤累积方面优于SLEDAI-2K。

研究设计与样本

  • 纳入林雪平大学医院2008至2025年间至少2次访视的SLE患者,前瞻性评估SLEDAI-2K和PhGA,回顾性计算SLE-DAS。
  • 每年用SLICC/ACR损伤指数(SDI)评估器官损伤,并计算访视间期的平均SLEDAI-2K、平均PhGA和平均SLE-DAS。
  • 采用时间依赖多变量Cox回归模型评估各指标预测损伤累积的能力,并用AIC和BIC比较预测能力。

主要发现

  • 共335例患者、3582次门诊访视贡献数据。
  • 平均SLE-DAS是SDI增加的独立预测因子:3年HR 1.04(95%CI 1.00-1.08),5年HR 1.05(95%CI 1.01-1.09),7年HR 1.04(95%CI 1.00-1.08)。
  • 平均SLEDAI-2K仅在5年随访中预测SDI增加:HR 1.12(95%CI 1.02-1.22)。
  • 平均PhGA在5年(HR 1.99,95%CI 1.19-3.36)和7年(HR 1.84,95%CI 1.02-3.30)预测SDI增加。
  • 平均SLE-DAS在3年、5年和7年随访中预测损伤累积的能力高于平均SLEDAI-2K,表现为AIC和BIC更低。

临床怎么用

  • 在SLE长期管理中,可优先采用SLE-DAS动态评估疾病活动度以辅助预测器官损伤风险。
  • 对平均SLE-DAS较高的患者应加强器官损伤监测与干预。

局限性

  • SLE-DAS为回顾性计算,可能存在信息偏倚。
  • 研究为单中心真实世界队列,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: SLE remains a heterogeneous autoimmune disease that can lead to irreversible organ damage. SLE Disease Activity Score (SLE-DAS) is a recently developed tool with higher sensitivity to change than SLE Disease Activity Index-2000 (SLEDAI-2K). We compared SLE-DAS with other activity measures in terms of ability to predict organ damage. METHODS: Patients from Linköping University Hospital with ≥2 visits between 2008 and 2025 were included. SLEDAI-2K and Physician's Global Assessment (PhGA) were assessed prospectively, and SLE-DAS retrospectively. Organ damage was estimated annually using the SLICC/ACR Damage Index (SDI). Adjusted mean scores of SLEDAI-2K (amSLEDAI-2K), PhGA (amPhGA) and SLE-DAS (amSLE-DAS) were determined for each time interval between consecutive visits, and their ability to predict damage accrual was evaluated using time-dependent multivariable Cox regression models. Predictive ability was compared across measures using Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). RESULTS: In total, 335 patients with 3582 outpatient visits contributed data. amSLE-DAS was an independent predictor of SDI increase at the 3- (HR; 95% CI: 1.04; 1.00-1.08), 5- (1.05; 1.01-1.09) and 7-year follow-up (1.04; 1.00-1.08). amSLEDAI-2K was predictive at the 5-year follow-up only (1.12; 1.02-1.22), and amPhGA at 5 (1.99; 1.19-3.36) and 7 (1.84; 1.02-3.30) years. amSLE-DAS showed a higher predictive ability for damage accrual than amSLEDAI-2K at the 3-, 5- and 7-year follow-up, as indicated by lower AIC and BIC. CONCLUSION: In this real-world Swedish setting, we demonstrate that SLE-DAS outperforms SLEDAI-2K in predicting organ damage accrual in SLE, substantiating its clinical relevance.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Andraos R, Tsoi A, Kastbom A, et al. Ability of SLE-DAS and SLEDAI-2K to predict damage accrual in SLE: a real-world 7-year cohort study from Sweden. Rheumatology (Oxford). 2026. PMID: 42811191. doi:10.1093/rheumatology/keag545

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。